NEW YORK (awp international) – After a weak end of the week, the US stock exchanges are heading for further losses on Monday. Analyst Craig Erlam from broker Oanda identified several negative factors with the effects of the Corona variant Omikron, the monetary policy tightening plans of the major central banks and the impending failure of President Joe Biden’s social and climate plans.
Over half an hour before the start of trading, the broker IG valued the Dow Jones Industrial 1.19 percent lower to 34,945 points. The technology-heavy Nasdaq 100, which had fared significantly better than the leading index on Friday, is expected to be 1.49 percent in the red at 15,565 points.
The shareholders of corona vaccine manufacturers can look forward to renewed price gains. The recently strong Novavax stocks increased in price by almost eight and a half percent before the market, after the EU medicines agency EMA paved the way for approval of its vaccine. After approval by the EU Commission, this will be the fifth corona vaccine in the EU. The responsible commission of experts issued the recommendation after an extraordinary meeting.
The shares in Biontech listed in New York rose by almost three percent before the market. The Mainz corona vaccine pioneer and its US partner Pfizer are supplying the EU with an additional 20 million doses of their joint vaccine for the first three months of 2022 because of Omikron. This brings the total number of expected deliveries from Biontech / Pfizer to the EU in the first quarter to 215 million.
A similar agreement had been concluded with the manufacturer Moderna, the EU Commission said. Its shares also benefited with a plus of a good eight percent from the fact that a booster with the Moderna vaccine significantly increases the body’s immune defense against Omikron, according to the manufacturer. / Gl / jha /
– .
